16/09/2022
Telebionix has officially accepted admission to the CDL-Vancouver 2022/2023 Cohort. To be part of this program designed for early-stage, science-based technology companies, given their potential to scale and the viability of their product, is both humbling and encouraging to keep pushing and bring the Remosense to market. This is more evidence of our belief that healthcare should be accessible to all, paired with the right technology is making waves.
Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies.
CDL has designed a new approach to enterprising research and innovation, nurturing an entrepreneurial mindset through expert opinion, funding opportunities, research analysis, and business development support.
